Interleukin-1β (IL-1β) exerts context-dependent effects in cancer immunity, promoting both inflammatory tumor progression and antitumor immune responses. The IL1B promoter single-nucleotide polymorphism rs16944 has been associated with poor prognosis in hepatocellular carcinoma, yet its functional impact on immune signaling remains unclear. Here, we used prime editing to generate LSEC-like SK-Hep-1 cells enriched for the rs16944 A allele through precise conversion from the endogenous G/G genotype. The edited cell population exhibited a marked reduction in IL1B mRNA expression and IL-1β secretion without detectable changes in basal endothelial or innate immune surface marker expression. Transcriptomic profiling by RNA sequencing revealed coordinated suppression of cytokine- and chemokine-related genes, including IL1B , CCL2 , CXCL2 , CXCL8 , and IL6 , accompanied by increased ITGA5 expression. Cytometric bead array analysis further demonstrated significantly reduced secretion of IL-8/CXCL8, MCP-1/CCL2, RANTES/CCL5, and MIG/CXCL9, providing protein-level evidence of an altered immune-related secretory profile. Restoration of IL-1β by transient overexpression selectively rescued cytokine and chemokine expression. These findings demonstrate that rs16944 A-allele enrichment is associated with reduced IL-1β expression and broad alterations in immune-related transcriptional and secretory programs, emphasizing the importance of the IL1B genotype in tumor immunology research.
No takes yet. Share an insight, caveat, or question.
Namba et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Scientific Reports